Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

zagociguat

Phase 2Small molecule

TTisento Therapeutics

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)Active, not recruiting

Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)Phase 2

Active, not recruiting

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

NCT06961344

Clinical

Trials by Indication[1]

Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)2 trials

Phase 2b Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of Zagociguat in Participants With MELAS (PRIZM)

Completed·TTisento Therapeutics·Phase 2·NCT06402123·43 enrolled

An Open-label Extension Study Evaluating the Safety of Zagociguat in Participants With MELAS Who Completed TIS6463-203

Active, not recruiting·TTisento Therapeutics·Phase 2·NCT06961344·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for zagociguat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zagociguat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zagociguat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tisento Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTisento Therapeutics

Related News